Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide for Endothelial Protection in Post-COVID-19 Patients
NCT05371925Phase 3Completed
- Sponsor
- Centro Médico del Noroeste
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sulodexide in post-COVID-19 condition (PCC), sponsored by Centro Médico del Noroeste. Started Jun 2023; status: completed.
02
Drugs
sulodexide
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT05371925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371925.